logo-loader
viewAvalon GloboCare Corp

Avalon GloboCare expands and files two patents for developing a decoy cytokine receptor-based filter system to treat ‘cytokine storms’

Patients infected with the SARS-CoV-2 virus that causes the coronavirus COVID-19 are susceptible to developing cytokine storms, which occur when the immune system suddenly produces high levels of inflammatory proteins called cytokines that concentrate in the blood

Avalon GloboCare Corp -
The provisional patent applications are direct results of recent advancements related to Avalon’s AVA-Trap therapeutic program

Avalon GloboCare Corp. (NASDAQ:AVCO) announced that it has expanded and filed two provisional patents with the US Patent and Trademark Office outlining compositions and methods of developing a decoy cytokine receptor-based filter system to treat ‘cytokine storms’. 

The clinical-stage global developer of cell-based technologies and therapeutics said these provisional patent applications are direct results of recent advancements related to Avalon’s AVA-Trap therapeutic program.

The technology utilizes cytokine receptor–Fc-fusion proteins to potentially serve as an antibody-like decoy to dampen the excessive cytokine release that occurs during hyper-activation of the immune system—a life-threatening condition called “cytokine storm” that can cause multi-organ failure and death.

READ: Avalon GloboCare successfully completes Phase I first-in-human clinical study of its leading Chimeric Antigen Receptor (CAR) T-cell therapy candidate

Patients infected with the SARS-CoV-2 virus that causes the coronavirus COVID-19 are susceptible to developing cytokine storms, which occur when the immune system suddenly produces high levels of inflammatory proteins called cytokines that concentrate in the blood.

The extracorporeal hemo-purifier device is designed to provide potential treatment for patients experiencing cytokine storms induced by COVID-19, hepatitis, HIV, influenza, graft-versus-host disease, and cytokine release syndrome associated with CAR-T cell therapy.

The company said the expanded patent application was jointly filed with Professor Shuguang Zhang of the Massachusetts Institute of Technology (MIT) Media Lab, and Professor Uwe Sleytr, a full member of the Austrian Academy of Sciences and pioneer of applied surface layer (“S-layer”) nanotechnology.

The application combines Avalon’s AVA-Trap program with two innovative technologies. The first is the QTY code protein design platform, which was developed together with Professor Shuguang Zhang’s laboratory at MIT. This technology platform can turn water-insoluble proteins that normally reside within cellular membranes—and that can be difficult to work within the laboratory—into water-soluble proteins that can be used in many clinical applications.

The second technology is applied S-layer nanotechnology, based on the repetitive protein structures that make up the outer surface of microbial cells.  Coating of S-layers on solid surfaces can greatly enhance the binding orientation and efficiency of targeted ligand proteins that are directed to bind to, and capture, molecules of choice in the blood.

Together, Avalon is developing these unique technologies to advance an extracorporeal hemodialysis and hemo-purification device consisting of membrane protein receptors for specific cytokines coated onto an S-layer-based matrix that can be used to specifically filter out cytokines responsible for a “cytokine storms” in patients experiencing this immune system attack on the body, including patients with COVID-19.

While non-specific blood filtration systems exist, the clinical AVA-Trap blood filtration system would specifically target cytokine storm-causing proteins, allowing the detection and recovery of cytokines—and serving as a potential clinical therapy as well as a diagnostic tool. Importantly, it is the Company’s goal to develop a filtration system that can be customized to trap only specific molecules.

In a statement, David Jin, president and chief executive officer of Avalon said: “We are grateful for our strong scientific partnerships that enabled the rapid speed with which we are developing this novel clinical tool.”

“This medical device holds enormous promise as it directly addresses a leading cause of mortality for patients with illnesses that make them vulnerable to the damaging effects of a cytokine storm,” he added.

Avalon GloboCare is a clinical-stage, vertically-integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well as COVID-19 related diagnostics and therapeutics.

Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth and development, as well as competitiveness in healthcare and CellTech industry markets. 

Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX), and regenerative therapeutics.

Contact the author at [email protected]

Quick facts: Avalon GloboCare Corp

Price: 1.3 USD

NASDAQ:AVCO
Market: NASDAQ
Market Cap: $104.09 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Avalon GloboCare Corp named herein, including the promotion by the Company of Avalon GloboCare Corp in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Avalon Globocare Corp seeing success working in the celltech space

Avalon GloboCare CEO (NASDAQ:AVCO) Dr. David Jin sat down with Proactive's Steve Darling at the 12th annual LD Micro Conference. The company is a clinical-stage CellTech bio-developer specializing in cellular therapeutics. Dr Jin talked about success in 2019 and what he expects in 2020.

on 10/12/19

4 min read